RECENT PAPERS from PubMed – November 11, 2023 – Tirzepatide and Cancer

• In adults with HF with preserved ejection fraction and obesity, tirzepatide reduced a composite of CV death or worsening HF at 2 y March 31, 2025
  GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text] Endocrinology: [Formula: see text].
  Leslie A Ynalvez
• The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Attenuates Colon Cancer Development by Regulating Glucose Metabolism March 24, 2025
  Colorectal cancer (CRC) is a leading cause of cancer mortality while diabetes is a recognized risk factor for CRC. Here we report that tirzepatide (TZP), a novel polypeptide/glucagon-like peptide 1 receptor (GIPR/GLP-1R) agonist for the treatment of diabetes, has a role in attenuating CRC growth. TZP significantly inhibited colon cancer cell proliferation promoted apoptosis in […]
  Yikai Zhang
• Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database March 8, 2025
  CONCLUSION: The study, based on data from the FAERS database, suggests a potential association between GLP-1 receptor agonists and an increased thyroid cancer risk. These findings underscore the importance of further research and continuous safety monitoring when prescribing these medications for obesity management.
  Christophe Abi Zeid Daou
• Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses? March 5, 2025
  Albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, orforglipron and semaglutide are glucagon-like peptide‑1 (GLP-1) receptor agonists. Tirzepatide targets not only GLP‑1 but also glucose-dependent insulinotropic peptide (GIP) receptors and retatrutide is a triple GLP‑1, GIP and glucagon receptor agonist. The GLP‑1 receptor agonists increase insulin release but suppress glucagon release. They slow down the emptying of the […]
  Hubertus Himmerich
• Regional trends and disparities in newer GLP1 receptor agonist initiation among real-world adult patients eligible for obesity treatment March 4, 2025
  CONCLUSIONS: The initiation of newer AOMs among overweight and obese populations remains low, but uptake has increased exponentially since 2022. Our findings reveal significant disparities in obesity care, highlighting the importance of addressing inequities in AOM access to improve obesity outcomes.
  Rotana M Radwan
• Tirzepatide alleviates doxorubicin-induced cardiotoxicity via inhibiting HRD1-mediated Nrf2 ubiquitination March 4, 2025
  CONCLUSIONS: Our study suggested that TZP attenuated oxidative stress and cardiomyocyte apoptosis by modulating HRD1-mediated Nrf2 expression and activity, thereby protecting against the cardiotoxic effects exerted by DOX. These results supported that TZP might be a promising therapeutic option for reducing chemotherapy-related cardiotoxicity.
  Dan Yang
• Treatment of obesity: will incretin agonists make bariatric surgery a thing of the past? February 21, 2025
  The prevalence of obesity continues to increase worldwide. Obesity is associated with an increased risk of cardiometabolic and other diseases, reduced quality of life and shortened life expectancy. Highly effective therapies are required to achieve meaningful and sustained weight reduction to prevent, slow or reverse disease associated with obesity. Bariatric surgery is a highly effective […]
  Siehoon Lah
• Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis February 17, 2025
  CONCLUSION: Short-term data from RCTs with low RoB suggests that tirzepatide positively impacts UACR without detrimental effects on eGFR in subjects with T2D and obesity without T2D, with a reassuring renal safety profile. Larger RCTs are warranted to prove the longer-term renal benefits of tirzepatide, which might also prevent eGFR decline and worsening of CKD.
  Abm Kamrul-Hasan
• Nutrient-Stimulating Hormone-Based Therapies for Obesity February 7, 2025
  Obesity is a chronic disease with an increasing worldwide prevalence. Improving obesity is of paramount importance given its association with conditions such as type 2 diabetes, cardiovascular disease, and cancer among others. In the last decade, a new class of highly efficacious medications called nutrient-stimulating hormone (NuSH) therapies has emerged. This article highlights the effectiveness […]
  Cagney Cristancho
• Appendicitis After Initiation of Tirzepatide February 5, 2025
  Tirzepatide is a GLP1/GIP receptor agonist that is used to treat type 2 diabetes and promote weight loss. Common side effects of Tirzepatide include nausea, vomiting, and diarrhea. More severe side effects include pancreatitis, cholelithiasis, thyroid cancer, and cholecystitis. With the increased use of these medications, additional side effects are being discovered. Delayed gastric emptying […]
  Garrett Chan
• Association of long-term weight management pharmacotherapy with multiple health outcomes: an umbrella review and evidence map January 26, 2025
  CONCLUSIONS: This umbrella review identified significant beneficial associations between pharmacotherapies and anthropometric measures, lipid profile, blood pressure, glycemic profile, and quality-of-life outcomes in individuals with overweight or obesity. In addition, the umbrella review highlighted safety considerations. The findings affirm the efficacy of the six pharmacotherapies in promoting weight loss in this demographic. Further clinical trials […]
  Ting-Ting Lu
• Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis January 15, 2025
  CONCLUSION: Tirzepatide use in RCTs over 26 to 72 weeks did not increase overall or specific cancer risk.
  A B M Kamrul-Hasan
• Adropin/Tirzepatide Combination Mitigates Cardiac Metabolic Aberrations in a Rat Model of Polycystic Ovarian Syndrome, Implicating the Role of the AKT/GSK3beta/NF-kappaB/NLRP3 Pathway January 11, 2025
  Polycystic ovarian syndrome (PCOS) is a multifaceted metabolic and hormonal disorder in females of reproductive age, frequently associated with cardiac disturbances. This research aimed to explore the protective potential of adropin and/or tirzepatide (Tirze) on cardiometabolic aberrations in the letrozole-induced PCOS model. Female Wistar non-pregnant rats were allotted into five groups: CON; PCOS; PCOS + […]
  Islam Ibrahim Hegab
• Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics January 10, 2025
  Clinical studies have suggested that tirzepatide may also possess hepatoprotective effects; however, the molecular mechanisms underlying this association remain unclear. In our study, we performed biochemical analyses of serum and histopathological examinations of liver tissue in mice. To preliminarily explore the molecular mechanisms of tirzepatide on metabolic dysfunction-associated fatty liver disease (MAFLD), liquid chromatography-mass spectrometry […]
  Jinliang Liang
• Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: an integrative analysis across multiple tumor types January 8, 2025
  Glucagon-like peptide-1 receptor (GLP-1R) agonists, such as exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), albiglutide (Tanzeum), dulaglutide (Trulicity), lixisenatide (Lyxumia, Adlyxin), semaglutide (Ozempic, Rybelsus, Wegovy), and tirzepatide (Mounjaro, Zepbound), are widely used for the treatment of type 2 diabetes mellitus (T2DM) and obesity. While these agents are well known for their metabolic benefits, there is growing […]
  Zoltan Ungvari
• Anti-Diabetic Therapies and Cancer: From Bench to Bedside November 27, 2024
  Diabetes mellitus (DM) is a significant risk factor for various cancers, with the impact of anti-diabetic therapies on cancer progression differing across malignancies. Among these therapies, metformin has gained attention for its potential anti-cancer effects, primarily through modulation of the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) pathway and the induction of autophagy. Beyond metformin, […]
  Dimitris Kounatidis
• Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as treatment for nicotine cessation in psychiatric populations: a systematic review November 11, 2024
  CONCLUSION: The multi-effect characteristics in NUD paradigms provide a compelling rationale for large, adequately powered, long-term, randomized controlled trials of GLP-1RAs in the treatment and prevention of NUD. The replicated effect on mitigating post-nicotine cessation weight gain is a differentiating feature of GLP-1RAs from extant proven therapies for NUD.
  Serene Lee
• A systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: Target engagement and rationale for the development in mental disorders November 8, 2024
  INTRODUCTION: The mechanistic role of glucagon-like peptide-1 (GLP-1) and GLP-1 receptor agonists (GLP-1RAs) in modulating brain functional activity has been inadequately examined. Mental disorders are characterized by dysregulated functional connectivity in brain circuits that subserve phenomenology. We conducted a comprehensive synthesis of known effects of GLP-1 and GLP-1RAs on functional connectivity.
  Hezekiah C T Au
• Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®) October 21, 2024
  CONCLUSION: Unlike our previous report with FAERS, a mixed pattern of ROR emerged in the WHO VigiBase with respect to suicidality and exposure to select GLP-RAs. Causation between GLP-1 RA exposure and suicidality (either increased or decreased) cannot be ascertained from ROR data.
  Roger S McIntyre
• Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer October 10, 2024
  CONCLUSION: Tirzepatide decreased both mouse weight and tumor growth via effects on metabolic and immune pathways in the EC tumors that differed between obese and lean mice. This novel weight loss treatment deserves further evaluation as an innovative strategy in the management of EC.
  Weimin Kong